Abstract
Patients with primary sclerosing cholangitis (PSC) are at an increased risk for biliary tract carcinoma. The preoperative diagnosis of a biliary tract tumor as a malignancy is difficult, even using new modalities such as multidetector computed tomography (MD-CT), magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiography (ERC), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Surgery is considered to be first line of treatment when these examinations suggest the presence of malignancy in the biliary tract, depending on both the curability of the cancer and the impaired liver function due to PSC. The management of gallbladder masses in patients with PSC remains problematic due to difficulties with the precise diagnosis and adequate surgery. Xanthogranulomatous cholecystitis (XGC) is a type of chronic cholecystitis, and sometimes coexists with gallbladder cancer. It is very difficult to make a preoperative diagnosis differentiating these two diseases. This report presents the case of a patient with XGC, who had been suspected of having gallbladder cancer before surgery, because the tumorous lesion emerged within a year and showed a focally increased uptake by FDG-PET during the follow up for PSC for years. This is the first case of XGC discovered during treatment for PSC.
Similar content being viewed by others
References
Nilsson I, Kornilovs’ka I, Lindgren S, Ljungh A, Wadstrom T. Increased prevalence of seropositivity for non-gastric Helicobacter species in patients with autoimmune liver disease. J Med Microbiol 2003;52:949–953.
Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998;351:1620–1624.
Ponsioen CY, Defoer J, Ten Kate FJ, Weverling GJ, Tytgat GN, Pannekoek Y, et al. A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? Eur J Gastroenterol Hepatol 2002;14:641–648.
Karrar A, Broomé U, Södergren T, Jaksch M, Bergquist A, Björnstedt M, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007;132:1504–1514.
Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008;48:598–605.
Brandsaeter B, Isoniemi H, Broomé U, Olausson M, Bäckman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40:815–822.
Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002;97:1138–1142.
Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321–327.
Kobayashi H, Hosotani R, Imai Y, Wada K, Kajiwara T. Primary sclerosing cholangitis in which differential diagnosis from gallbladder carcinoma was difficult. J Hepatobiliary Pancreat Surg 2005;12:151–154.
Mori M, Watanabe M, Sakuma M, Tsutsumi Y. Infectious etiology of xanthogranulomatous cholecystitis: Immunohistochemical identification of bacterial antigens in the xanthogranulomatous lesions. Pathol Int 1999;49:849–852.
Sawada S, Harada K, Isse K, Sato Y, Sasaki M, Kaizaki Y. et al. Involvement of Escherichia coli in pathogenesis of xanthogranulomatous cholecystitis with scavenger receptor class A and CXCL16-CXCR6 interaction. Pathol Int 2007;57:652–663.
Guzmán-Valdivia G. Xanthogranulomatous cholecystitis: 15 years’ experience. World J Surg 2004;28:254–257.
Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8:90–97.
Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol 2003;84:74–81.
Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Van Steenbergen W. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2005;43:358–360.
Prytz H, Keiding S, Bjornsson E, Broomé U, Almer S, Castedal M, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006;44:1572–1580.
Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007;34:2088–2095.
Clarke T, Matsuoka L, Jabbour N, Mateo R, Genyk Y, Selby R, et al. Gallbladder mass with a carbohydrate antigen 19-9 level in the thousands: malignant or benign pathology? Report of a case. Surg Today 2007;37:342–344.
Spinelli A, Schumacher G, Pascher A, Lopez-Hanninen E, Al-Abadi H, Benckert C, et al. Extended surgical resection for xanthogranulomatous cholecystitis mimicking advanced gallbladder carcinoma: A case report and review of literature. World J Gastroenterol 2006;12:2293–2296.
Enomoto T, Todoroki T, Koike N, Kawamoto T, Matsumoto H. Xanthogranulomatous cholecystitis mimicking stage IV gallbladder cancer. Hepatogastroenterology 2003;50:1255–1258.
Kwon AH, Matsui Y, Uemura Y. Surgical procedures and histopathologic findings for patients with xanthogranulomatous cholecystitis. J Am Coll Surg 2004;199:204–210.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mori, A., Doi, R., Yonenaga, Y. et al. Xanthogranulomatous cholecystitis complicated with primary sclerosing cholangitis: Report of a case. Surg Today 40, 777–782 (2010). https://doi.org/10.1007/s00595-009-4138-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-009-4138-y